{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:33:23Z","timestamp":1786984403772,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.antiviral.2011.11.010","type":"journal-article","created":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T05:39:40Z","timestamp":1322717980000},"page":"160-166","source":"Crossref","is-referenced-by-count":24,"title":["Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge"],"prefix":"10.1016","volume":"93","author":[{"given":"Inge","family":"Vliegen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2011.11.010_b0005","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1128\/JVI.65.11.5910-5920.1991","article-title":"Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein","volume":"65","author":"Blasco","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0010","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1128\/JVI.66.7.4170-4179.1992","article-title":"Role of cell-associated enveloped vaccinia virus in cell-to-cell virus spread","volume":"66","author":"Blasco","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1099\/0022-1317-80-2-425","article-title":"Complementation of P37 (F13L gene) knock-out in vaccinia virus by a cell line expressing the gene constitutively","volume":"80","author":"Borrego","year":"1999","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0020","first-page":"86","article-title":"Differences between extracellular and intracellular forms of poxvirus and their implications","volume":"16","author":"Boulter","year":"1973","journal-title":"Prog. Med. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0166-3542(03)00008-1","article-title":"Pathogenesis and potential antiviral therapy of complications of smallpox vaccination","volume":"58","author":"Bray","year":"2003","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.11.010_b0030","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1177\/135965350801300817","article-title":"Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently","volume":"13","author":"Duraffour","year":"2008","journal-title":"Antivirus Ther."},{"key":"10.1016\/j.antiviral.2011.11.010_b0035","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1099\/vir.0.81090-0","article-title":"Ectromelia virus: the causative agent of mousepox","volume":"86","author":"Esteban","year":"2005","journal-title":"J Gen. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0040","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1128\/JVI.62.2.367-375.1988","article-title":"High levels of genetic recombination among cotransfected plasmid DNAs in poxvirus-infected mammalian cells","volume":"62","author":"Evans","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0045","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0042-6822(59)90051-0","article-title":"Genetic studies with mammalian poxviruses. II. Recombination between two strains of vaccinia virus in single HeLa cells","volume":"8","author":"Fenner","year":"1959","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.11.010_b0050","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.antiviral.2011.11.010_b0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clindermatol.2005.11.009","article-title":"The history of smallpox","volume":"24","author":"Geddes","year":"2006","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0060","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1128\/JVI.72.6.5108-5120.1998","article-title":"Analysis of a vaccinia virus mutant expressing a nonpalmitylated form of p37, a mediator of virion envelopment","volume":"72","author":"Grosenbach","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0065","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fvl.11.27","article-title":"Development of the small-molecule antiviral ST-246 as a smallpox therapeutic","volume":"6","author":"Grosenbach","year":"2011","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0070","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.antiviral.2005.11.006","article-title":"Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R","volume":"69","author":"Gurt","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.11.010_b0075","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1128\/JVI.00034-07","article-title":"The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus","volume":"81","author":"Honeychurch","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0080","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/v2102213","article-title":"Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate","volume":"2","author":"Hostetler","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2011.11.010_b0085","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1128\/JVI.29.2.705-715.1979","article-title":"Vaccinia virus replication. I. Requirement for the host\u2013cell nucleus","volume":"29","author":"Hruby","year":"1979","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0090","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1128\/JVI.75.16.7528-7542.2001","article-title":"Vaccinia virus F13L protein with a conserved phospholipase catalytic motif induces colocalization of the B5R envelope glycoprotein in post-Golgi vesicles","volume":"75","author":"Husain","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0095","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1128\/JVI.76.15.7777-7789.2002","article-title":"Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D","volume":"76","author":"Husain","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2011.11.010_b0105","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.vaccine.2008.03.044","article-title":"Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination","volume":"26","author":"Jentarra","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2011.11.010_b0110","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1128\/AAC.01303-07","article-title":"Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor","volume":"52","author":"Jordan","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.11.010_b0115","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1128\/JVI.77.22.12266-12275.2003","article-title":"Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein","volume":"77","author":"Katz","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0120","doi-asserted-by":"crossref","first-page":"11637","DOI":"10.1128\/JVI.76.22.11637-11644.2002","article-title":"Identification of second-site mutations that enhance release and spread of vaccinia virus","volume":"76","author":"Katz","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1045-1870(03)00032-3","article-title":"Adverse events occurring after smallpox vaccination","volume":"14","author":"Lane","year":"2003","journal-title":"Semin. Pediatr. Infect. Dis."},{"key":"10.1016\/j.antiviral.2011.11.010_b0130","series-title":"Fields Virology","article-title":"Poxviridae and their replication","author":"Moss","year":"2001"},{"key":"10.1016\/j.antiviral.2011.11.010_b0135","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","article-title":"Efficacy of cidofovir in a murine model of disseminated progressive vaccinia","volume":"48","author":"Neyts","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2011.11.010_b0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-50-1-89","article-title":"Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia","volume":"50","author":"Payne","year":"1980","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0145","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/JVI.72.5.4192-4204.1998","article-title":"The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus","volume":"72","author":"Roper","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2144\/000112012","article-title":"Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker","volume":"39","author":"S\u00e1nchez-Puig","year":"2005","journal-title":"Biotechniques"},{"key":"10.1016\/j.antiviral.2011.11.010_b0155","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.vaccine.2007.11.045","article-title":"Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination","volume":"26","author":"Vijaysri","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2011.11.010_b0160","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1128\/JVI.71.5.3904-3915.1997","article-title":"The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus","volume":"71","author":"Wolffe","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/viro.1998.9103","article-title":"Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread","volume":"244","author":"Wolffe","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2011.11.010_b0170","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.3390\/v2102381","article-title":"Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections","volume":"2","author":"Xiao","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2011.11.010_b0175","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2011.11.010_b0180","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1128\/JVI.77.13.7281-7290.2003","article-title":"High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells","volume":"77","author":"Yao","year":"2003","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211005110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354211005110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T06:26:33Z","timestamp":1686464793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354211005110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0166354211005110"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2011.11.010","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}